Objective To investigate the clinical efficacy of programmed death receptor 1 (PD-1) inhibitor combined with chemotherapy or anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC).
Methods The clinical data of 44 patients with advanced non-small cell lung cancer from the First Affiliated Hospital of Bengbu Medical University from December 2020 to December 2022 were retrospectively analyzed. The patients were divided into the A group and B group (22 cases each group) according to the treatment regimen. The A group were treated with PD-1 inhibitor combined with chemotherapy drugs, and B group were treated with PD-1 inhibitor combined with anlotinib. The clinical efficacy, survival and adverse drug reactions were compared between two groups.
Results The disease control rate (DCR) in the B group was 90.91%, which was significantly higher than that in A group (59.09%) (P ＜ 0.05). There was no statistical significances in the progression-free survival (PFS) and overall survival (OS) between two groups (P ＞ 0.05). During the treatment period, the incidence rates of adverse reactions (including the blood toxicity and gas trointestinal reactions) in B group were significantly less than those in A group (P ＜ 0.05).
Conclusions PD-1 inhibitor combined with antirotinib in the treatment of advanced NSCLC has a similar therapeutic effect as PD-1 inhibitor combined with chemotherapy, and the adverse reactions significantly reduce.
DownLoad: